Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 616 to 630 of 702 results for end of life care

  1. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  2. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  3. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)

    Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.

  4. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

  5. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  6. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

  7. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  8. ImmunoCAP ISAC 112 for multiplex allergen testing (HTG413)

    Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.

  9. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  10. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

  11. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  12. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

  13. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTG694)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.

  14. Phrenic nerve transfer in brachial plexus injury (HTG322)

    Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.

  15. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.